KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Equity Income (2016 - 2026)

West Pharmaceutical Services has reported Equity Income over the past 18 years, most recently at $3.4 million for Q1 2026.

  • Quarterly Equity Income changed 0.0% to $3.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $14.4 million through Mar 2026, up 4.35% year-over-year, with the annual reading at $14.4 million for FY2025, 2.04% down from the prior year.
  • Equity Income was $3.4 million for Q1 2026 at West Pharmaceutical Services, down from $3.9 million in the prior quarter.
  • Over five years, Equity Income peaked at $7.2 million in Q1 2022 and troughed at $2.0 million in Q4 2024.
  • The 5-year median for Equity Income is $3.9 million (2024), against an average of $4.2 million.
  • Peak annual rise in Equity Income hit 95.0% in 2025, while the deepest fall reached 46.15% in 2025.
  • Tracing WST's Equity Income over 5 years: stood at $3.2 million in 2022, then rose by 3.12% to $3.3 million in 2023, then crashed by 39.39% to $2.0 million in 2024, then surged by 95.0% to $3.9 million in 2025, then dropped by 12.82% to $3.4 million in 2026.
  • According to Business Quant data, Equity Income over the past three periods came in at $3.4 million, $3.9 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.